Fate Therapeutics, Inc.
vista's key points
- Fate Therapeutic's cell therapy product candidate pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell product candidates derived from master iPSC lines, and an immuno-regulatory program developed to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation.
On January 4th, Fate announced the closing of an underwritten public offering of 5,122,807 shares of its common stock, which included 701,754 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $85.50 per share. In addition,...Read More
Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.
Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.Get Free Email Updates